OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

STAS in Stage I Lung Adenocarcinoma Is More Than a Histologic Finding: Multi-Omic Profiling Reveals an Aggressive Molecular Phenotype

Atezolizumab Plus Gemcitabine/Cisplatin in Metastatic Urothelial Cancer

Robin Zon: ASCO Highlights Medicaid Policy Changes and Continuity of Cancer Care

Patrizia Giannatempo: A New Perioperative Era in MIBC

WHO Flags Six Essential Childhood Cancer Medicines Facing Critical Access Gaps

Oncology News, Insights, Stories by OncoDaily

Immuno 2026
Not To Miss

Immunõ 2026: Where Is Cancer Immunotherapy Heading Next?

Imlunestrant Plus Abemaciclib
Breast Oncology

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy

Highlights from SIOP 2026
Not To Miss

Highlights from SIOP 2026

Highlights from WCLC 2026

Narjust Florez: Key Insights From WCLC 2026

Pat Soon-Shiong: The Most Precise Cancer Target Ever Discovered

New Paper Alert: Antiseizure Drug Levetiracetam Linked to Longer Survival in Diffuse Midline Glioma

ESMO Introduces 34 Social Media Ambassadors for ESMO Congress 2026

ADCs in GI Oncology: Current Clinical Evidence and Emerging Therapeutic Opportunities

Robin Zon: ASCO Highlights Medicaid Policy Changes and Continuity of Cancer Care

Voices
Remziye Semerci

Remziye Semerci։ Four Days of Science, Collaboration, and Meaningful Discussions in Pediatric Oncology Nursing

Expanding Access to Treatment for Patients Around the World - The Max Foundation

Marcin Kubeczko: Honoured to Have Received the University of Padova Award for Advances in Breast Cancer 2026

Ingrid Zhang։ Excited to Advance Legend Biotech’s Mission and Transform Patient Outcomes

Irene Cuervas Oliveras Receives the Odile Schweisguth Prize for Pediatric Oncology Research - Institut de Recerca Sant Joan de Déu

Debra Patt: Thoughtful AI Adoption Can Reduce Administrative Burden and Improve Care Delivery

Erika Hamilton: Honored to be Among the Ambassadors for ESMO26

FDA Approvals
Abemaciclib

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC

FDA Approves Curium’s Bexlutry (Lutetium Lu 177) for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

FDA Approves Floretyrosine F 18 for PET Imaging in Glioma

FDA Expands Accelerated Approval of Sevabertinib for HER2-Mutant Non-small Cell Lung Cancer

FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutated Advanced Breast Cancer

FDA Approves Ziihera With and Without Tislelizumab Plus Chemotherapy for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

OncoDaily 100
100 Influential Women

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Cancer Survivors on Social Media: 2026 Edition

100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2025

The 100 Most Influential CEOs in Oncology in 2025 (Full List)

Celebrities and Cancer

OncoCalendar

Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2026

Mayo Clinic

13 Nov
Hepato-Pancreatico-Biliary Cancer

The Caring for the Cancer Patient 2026

Mayo Clinic

05 Nov
Hepato-Pancreatico-Biliary Cancer

Mayo Clinic Multidisciplinary Update in Breast Disease 2026

Mayo Clinic

05 Nov
Hepato-Pancreatico-Biliary Cancer

10th Advances in Colorectal Oncology: Shaping the Future of Multidisciplinary Care

Memorial Sloan Kettering Cancer Center (MSK)

05 Nov
Advances in Colorectal Oncology

AACR-KCA Joint Conference on Precision Medicine in Cancer

American Association for Cancer Research (AACR)

12 Nov
AACR-KCA Joint Conference

Immune-oncology
The Big Questions in Cancer Immunotherapy: Can Cell Therapy Succeed in Solid Tumors?

The Big Questions in Cancer Immunotherapy: Can Cell Therapy Succeed in Solid Tumors?

The Big Questions in Cancer Immunotherapy: Are Personalized Cancer Vaccines Finally Ready to Deliver?

The Big Questions in Cancer Immunotherapy: Can the Gut Microbiome Shape Response to Immunotherapy?

Abalos Therapeutics Publishes New Data Supporting Arenavirus-Based Immunotherapy for Solid Tumors

The Big Questions in Cancer Immunotherapy: Why Do “Cold” Tumors Stay Invisible to the Immune System?

Trogocytosis in Cancer: How Cells Steal Each Other’s Proteins and Escape Immunotherapy

The Big Questions in Cancer Immunotherapy: Can We Predict Who Will Respond Before Treatment Starts?

Gastrointestinal-Oncology
GI Oncology

ADCs in GI Oncology: Current Clinical Evidence and Emerging Therapeutic Opportunities

Astellas Network Meta-Analysis Compares Zolbetuximab With ICI Regimens Across PD-L1 Subgroups in Advanced Gastric Cancer

PEGASUS Phase 2 Trial: ctDNA-Guided Adjuvant Therapy in Colon Cancer

Nivolumab With deb-TACE in Liver-Limited Hepatocellular Carcinoma

IMHOTEP: Perioperative Pembrolizumab in Localized dMMR/MSI Esophagogastric Cancer

MATTERHORN: Durvalumab Plus FLOT Improves OS in Resectable Gastric and GEJ Adenocarcinoma

10 Must-Read Posts In GI Oncology This Week

Breast-Oncology
Imlunestrant Plus Abemaciclib

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

Premenopausal HR+/HER2− Early Breast Cancer: Moving Beyond One-Size-Fits-All Adjuvant Therapy

Trastuzumab Deruxtecan Recommended for EU Approval in HER2-Positive Early Breast Cancer

ABC8 Guidelines Accepted for Publication: A More Molecular, Sequential, and Patient-Centered Framework for Advanced Breast Cancer

Japan Approves Enhertu Plus Pertuzumab and Datroway in Two New First-Line Metastatic Breast Cancer Settings

Japan Approves Trastuzumab Deruxtecan and Datopotamab Deruxtecan for New First-Line Metastatic Breast Cancer Indications

Lung-Oncology
STAS

STAS in Stage I Lung Adenocarcinoma Is More Than a Histologic Finding: Multi-Omic Profiling Reveals an Aggressive Molecular Phenotype

Beyond Pathological Stage: Multi-Omic Profiling Refines Recurrence Risk in Resected EGFR-Mutant Lung Adenocarcinoma

HARMONi-2 Shows Overall Survival Benefit With Ivonescimab Over Pembrolizumab in First-Line PD-L1–Positive NSCLC

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC

DESTINY-Lung04 Redefines First-Line Treatment in HER2-Mutant NSCLC, With PFS Benefit but No Current OS Advantage

ADAURA at WCLC 2026: 8-Year Survival Confirms Durable Benefit of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC

Tambotatug Pelitecan Delivers a Major Survival Gain in Relapsed SCLC: TAISHAN-302 Establishes B7-H3 as a Therapeutic Target

OncoDaily TV
Lynda Chin

The Future is Near. Can We Finally Stop Cancer Resistance? Dr. Lynda Chin

AI

Can you trust AI with your CANCER? Shaalan Beg

Christian Ntizimira

Continue to be human: Christian Ntizimira

Stephanie Kauffman

She Left Hollywood To Fight Cancer: Stephanie Kauffman

pablo allard

Childhood Cancer Survivor Who Changed the Law: Pablo Allard’s Advocacy Journey

Cancer Care

Personalizing Colorectal Cancer Care with ctDNA? Dr. Robert Lentz

Priti Patnaik, Independent journalism

Independent journalism in global health: Priti Patnaik

Treatment Paradigms, Karine Tawagi

Evolving Treatment Paradigms in Muscle-Invasive Bladder Cancer

Cancer in Women

Cancer in Women As a Global Health and Economic Issue: Dr. Maira Caleffi

oncoffee, palliative

ONCOFFEE: Colorectal Cancer, Palliative Care, and the Human Side of Oncology: Santiago Fontes

Empowering Oncologists

Empowering Oncologists: How Policy impacts Medicine?

WHO

Mission is possible: WHO said 2030 – Rwanda said 2027: Dr. Sabin Nsanzimana

Not To Miss
WCLC

Highlights from WCLC 2026

Immunõ 2026: Where Is Cancer Immunotherapy Heading Next?

Highlights from SIOP 2026

Trastuzumab Deruxtecan Recommended for EU Approval in HER2-Positive Early Breast Cancer

WHO Opens First-Ever Prequalification Pathway for 12 Childhood Cancer Medicines

Mendus Initiates Phase 1b DIVA Trial of Vididencel Plus Venetoclax and Azacitidine in Acute Myeloid Leukemia

Mosunetuzumab Plus Lenalidomide Improves PFS in Follicular Lymphoma in Phase 3 CELESTIMO Trial

OncoGrants
Yorkshire Cancer Research

Yorkshire Cancer Research COVID-19 Vaccination and Immunotherapy Funding Round 2026

Special Fellowship Funding

Yorkshire Cancer Research 2027 Special Fellowship Funding Round

Cancer Prevention

Yorkshire Cancer Research 2027 Funding Round: Advancing Cancer Prevention, Early Detection and Treatment

Senior Cancer Research

Cancer Research UK Senior Cancer Research Fellowship

Chordoma Foundation

CRI–Chordoma Foundation Impact Grant 2027

Laboratory Integration Program

CRI Clinic and Laboratory Integration Program 2027

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: Current Practice and Evolving Directions

CancerWorld

Oncologists
Saima Alvi

Saima Alvi

Oncologists Location
Iyad Sultan

Iyad Sultan

Oncologists Location Amman, Jordan
Roberto Carmagnani Pestana

Roberto Carmagnani Pestana

Oncologists Location São Paulo, Brazil
Md Imrul Kaes

Md Imrul Kaes

Oncologists Location Enayetpur, Bangladesh
Natalia Baran

Natalia Baran

Oncologists Location Bern, Switzerland
Fan Daiming

Fan Daiming

Oncologists Location Xi'an, China
Helena Kremer

Helena Kremer

Oncologists Location Rio de Janeiro, Brazil
Dirk Arnold

Dirk Arnold

Oncologists Location Hamburg, Germany

Oncology Drugs
OTX-2002: Innovative MYC-Targeting mRNA Therapy, Dose, Administration, and Clinical Trials

OTX-2002: Innovative MYC-Targeting mRNA Therapy, Dose, Administration, and Clinical Trials

mRNA-4359: Promising Cancer Vaccine, Dose, Administration, and Clinical Trials

BXCL701: Promising Innate Immune Activation, Dose, Administration, And Clinical Trials

NBTXR3: Promising Radioenhancer, Administration, Dose, And Clinical Trials

KT-333: Promising STAT3 Degradation, Dose, Administration, And Clinical Trials

Veliparib: Mechanism, Dose, Administration, And Clinical Trials

Adavosertib: Mechanism, Dose, Administration, And Clinical Trials

OncoDaily Magazine

New Paper Alert
Francesco Maura

Francesco Maura Shares AACR Journal Study on RHOA and CAR-T Resistance

Angela Lamarca

Angela Lamarca: Why Faster Diagnosis Matters in Early-Onset Cholangiocarcinoma

Levetiracetam

New Paper Alert: Antiseizure Drug Levetiracetam Linked to Longer Survival in Diffuse Midline Glioma

Yan Leyfman

Yan Leyfman: Can Bispecific Antibodies Break Through the CNS Lymphoma Barrier?

Zolbetuximab

Astellas Network Meta-Analysis Compares Zolbetuximab With ICI Regimens Across PD-L1 Subgroups in Advanced Gastric Cancer

Josh Drago

Josh Drago: What If We Are Missing Low-Level Targets That Are Rapidly Internalized?

OncoDaily Medical Journal

Pediatric Oncology

10.69690/ODMJ-011-0826-7849

Integrated Management of Endo and Exo-pelvic Sacrococcygeal Teratomas (Altman type III): Report of Two Cases
Case Reports & Case Series

Oncology Nursing

10.69690/ODMJ-001-0826-7778

Real-World Patterns of Immune-Related Toxicity in Gastrointestinal Cancer Patients Treated with Immunotherapy: A service evaluation
Original Research

Oncology Nursing

10.69690/ODMJ-002-0826-7795

Late presentation in cancer care: Implications for treatment and survival: A Narrative Review
Reviews

GI Oncology

10.69690/ODMJ-018-0826-7959

From Plate to Polyps: Dietary N-Nitrosamines and Biomarkers of DNA Damage
Abstracts

Head and Neck Cancer

10.69690/ODMJ-018-0826-7933

A Service Review of PD-L1 Biomarker Use in the Head and Neck Cancer Service
Abstracts

Radiation Oncology

10.69690/ODMJ-018-0826-7920

Short-Course Palliative Radiotherapy for Tumour-Related Bleeding in End-of-Life Care: A Focused Literature Review
Abstracts

Pediatric Oncology

10.69690/ODMJ-018-0826-7952

FLASH radiotherapy: A Potential Way to Protect the Developing Brain in Pediatric Oncology
Abstracts

GI Oncology

10.69690/ODMJ-018-0826-7947

Real World Clinical Insights in Combination of Trifluridine-Tipiracil with Bevacizumab for Metastatic Colorectal Cancer
Abstracts